Merck's New Oral PCSK9 Inhibitor Shows Promise in Lowering Cholesterol
TL;DR Summary
Merck announced promising Phase 3 trial results showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduces LDL cholesterol by over 55% with a safety profile similar to placebo, potentially offering a new oral treatment for cardiovascular disease prevention.
- Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial Merck.com
- Merck PCSK9 Pill Results Point to Extremely Low Cholesterol Future The New York Times
- More Drugs to Fight High Cholesterol Are Emerging The Wall Street Journal
- Merck’s pill to reduce cholesterol on top of statins matches results from injectables statnews.com
- Experimental daily pill may lower cholesterol in patients who don’t see enough benefit with statins alone, study finds CNN
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
9 min
vs 10 min read
Condensed
98%
1,815 → 40 words
Want the full story? Read the original article
Read on Merck.com